title: Blood luteinizing hormone and prolactin concentrations in response to naltrexone challenge: studies on rats with diabetes induced by different doses of streptozotocin.
abstract: Opiate system involvement in diabetes induced by three different doses of streptozotocin (STZ; 40, 50, and 60 mg/kg body weight [BW]) was studied by monitoring luteinizing hormone (LH) and prolactin (PRL) levels as a response to naltrexone (Nalt) administration. After four weeks of diabetes a marked decrease in BW, as well as severe hyperglycemia and increased blood urea nitrogen (BUN) levels were found. The rats, whose diabetes was induced by 50 mg/kg of STZ, exhibited the highest amount of blood glucose (P < 0.05, compared with the 40 mg/kg induced group) and BUN levels (P < 0.004 compared with the other two groups) and BW loss. The normal response to Nalt, which is expressed by elevation of plasma LH and decreased plasma PRL levels was observed only in the low-dose STZ (40 mg/kg BW) diabetes-induced group, while in the other two diabetic groups (50 and 60 mg/kg BW) there was no significant change in plasma LH and PRL as a result of the Nalt challenge. Presensitization of the endogenous opioid receptors by morphine in normoglycemic (control) and "low-dose diabetic" rats (40 mg/kg BW of STZ), presented a clear difference between the two. Morphine pretreatment inhibited LH response to Nalt in the low-dose, STZ-induced diabetic rats, while no effect of morphine pretreatment on LH response to Nalt could be recorded in the normoglycemic group. Thus it can be concluded that in STZ-induced diabetes, plasma glucose and BUN levels do not reflect the neuroendocrine injury observed when monitored by LH and PRL secretion in response to Nalt challenge. Supersensitization of the opioid receptors before the Nalt challenge may increase the ability to reveal neuroendocrine system impairment.
authors.affiliation: Institute for the Study of Fertility, Tel Aviv Sourasky Medical Center, Serlin Maternity Hospital, Israel.
authors.forename: L
authors.initials: L
authors.lastname: Yogev
authors.forename: H
authors.initials: H
authors.lastname: Yavetz
authors.forename: A
authors.initials: A
authors.lastname: Gottreich
authors.forename: D
authors.initials: D
authors.lastname: Oppenheim
authors.forename: Z T
authors.initials: ZT
authors.lastname: Homonnai
authors.forename: G
authors.initials: G
authors.lastname: Paz
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D007986:Luteinizing Hormone / Q000097:blood* / Q000378:metabolism; D008297:Male; D009271:Naltrexone / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011957:Receptors, Opioid / Q000187:drug effects / Q000502:physiology; D013311:Streptozocin / Q000008:administration & dosage
chemical_list: D001786:Blood Glucose; D011957:Receptors, Opioid; D009271:Naltrexone; D013311:Streptozocin; D011388:Prolactin; D007986:Luteinizing Hormone